Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Here, the authors use full-length Mpro protein as substrate and demonstrate that L50F can promote the formation of enzyme-substrate complex and thus contribute to nirmatrelvir resistance.

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

The following is a summary of “Evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality ...

Evidence shows weak antiviral activity and no improvement in symptom outcomes. Study: Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled ...

Bacterial pneumonia is most commonly caused by a bacteria called Streptococcus pneumoniae which accounts for around 50% of cases. Other common causes include Haemophilus influenzae, Chlamydia ...

A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness and ...

Study: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.